Longitudinal magnetic resonance imaging (MRI) has been proposed for tracking the progression of Alzheimer’s disease (AD) through the assessment of brain atrophy.
Objective:
Detection of brain atrophy patterns in patients with AD as the longitudinal disease tracker.
Methods:
We used a refined version of orthonormal projective non-negative matrix factorization (OPNMF) to identify six distinct spatial components of voxel-wise volume loss in the brains of 83 subjects with AD from the ADNI3 cohort relative to healthy young controls from the ABIDE study. We extracted non-negative coefficients representing subject-specific quantitative measures of regional atrophy. Coefficients of brain atrophy were compared to subjects with mild cognitive impairment and controls, to investigate the cross-sectional and longitudinal associations between AD biomarkers and regional atrophy severity in different groups. We further validated our results in an independent dataset from ADNI2.
Results:
The six non-overlapping atrophy components represent symmetric gray matter volume loss primarily in frontal, temporal, parietal and cerebellar regions. Atrophy in these regions was highly correlated with cognition both cross-sectionally and longitudinally, with medial temporal atrophy showing the strongest correlations. Subjects with elevated CSF levels of TAU and PTAU and lower baseline CSF Aβ42 values, demonstrated a tendency toward a more rapid increase of atrophy.
Conclusions:
The present study has applied a transferable method to characterize the imaging changes associated with AD through six spatially distinct atrophy components and correlated these atrophy patterns with cognitive changes and CSF biomarkers cross-sectionally and longitudinally, which may help us better understand the underlying pathology of AD.
LamB, MasellisM, FreedmanM, StussDT, BlackSE (2013) Clinical, imaging, and pathological heterogeneity of the Alzheimer’s disease syndrome. Alzheimers Res Ther5, 1.
2.
JellingerKA (2022) Recent update on the heterogeneity of the Alzheimer’s disease spectrum. J Neural Transm (Vienna)129, 1–24.
3.
KovacsGG (2012) Clinical stratification of subtypes of Alzheimer’s disease. Lancet Neurol11, 839–841.
WeinerMW, VeitchDP, AisenPS, BeckettLA, CairnsNJ, GreenRC, HarveyD, JackCR, JagustW, LiuE (2013) The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement9, e111–e194.
6.
PiniL, PievaniM, BocchettaM, AltomareD, BoscoP, CavedoE, GalluzziS, MarizzoniM, FrisoniGB (2016) Brain atrophy in Alzheimer’s disease and aging. Ageing Res Rev30, 25–48.
7.
WhitwellJL, DicksonDW, MurrayME, WeigandSD, TosakulwongN, SenjemML, KnopmanDS, BoeveBF, ParisiJE, PetersenRC, JackCRJr., JosephsKA (2012) Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: A case-control study. Lancet Neurol11, 868–877.
8.
JackCRJr., BarkhofF, BernsteinMA, CantillonM, ColePE, DecarliC, DuboisB, DuchesneS, FoxNC, FrisoniGB, HampelH, HillDL, JohnsonK, ManginJF, ScheltensP, SchwarzAJ, SperlingR, SuhyJ, ThompsonPM, WeinerM, FosterNL (2011) Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement7, 474–485.e4.
LiK, QuH, MaM, XiaC, CaiM, HanF, ZhangQ, GuX, MaQ (2022) Correlation between brain structure atrophy and plasma amyloid-β and phosphorylated tau in patients with Alzheimer’s disease and amnestic mild cognitive impairment explored by surface-based morphometry. Front Aging Neurosci14, 816043.
11.
WuB-S, ZhangY-R, LiH-Q, KuoK, ChenS-D, DongQ, LiuY, YuJ-T (2021) Cortical structure and the risk for Alzheimer’s disease: A bidirectional Mendelian randomization study. Transl Psychiatry11, 476.
12.
YangH, XuH, LiQ, JinY, JiangW, WangJ, WuY, LiW, YangC, LiX (2019) Study of brain morphology change in Alzheimer’s disease and amnestic mild cognitive impairment compared with normal controls. Gen Psychiatr32, e100005.
13.
MeintjesE, NarrK, Van Der KouweA, MoltenoC, PirniaT, GutmanB, WoodsR, ThompsonP, JacobsonJ, JacobsonS (2014) A tensor-based morphometry analysis of regional differences in brain volume in relation to prenatal alcohol exposure. Neuroimage Clin5, 152–160.
14.
HuaX, LeowAD, ParikshakN, LeeS, ChiangM-C, TogaAW, JackCR, WeinerMW, ThompsonPM (2008) Tensor-based morphometry as a neuroimaging biomarker for Alzheimer’s disease: An MRI study of 676 AD, MCI, and normal subjects. Neuroimage43, 458–469.
Ten KateM, DicksE, VisserPJ, van der FlierWM, TeunissenCE, BarkhofF, ScheltensP, TijmsBM, Alzheimer’s Disease Neuroimaging Initiative (2018) Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline. Brain141, 3443–3456.
21.
KimY, JiangX, GiancardoL, PenaD, BukhbinderAS, AmranAY, SchulzPE, Alzheimer’s Disease Neuroimaging Initiative (2020) Multimodal phenotyping of Alzheimer’s disease with longitudinal magnetic resonance imaging and cognitive function data. Sci Rep10, 5527.
22.
JinS, ZouP, HanY, JiangJ (2021) Unsupervised detection of individual atrophy in Alzheimer’s disease. Annu Int Conf IEEE Eng Med Biol Soc2021, 2647–2650.
23.
ShiR, ShengC, JinS, ZhangQ, ZhangS, ZhangL, DingC, WangL, WangL, HanY (2023) Generative adversarial network constrained multiple loss autoencoder: A deep learning-based individual atrophy detection for Alzheimer’s disease and mild cognitive impairment. Hum Brain Mapp44, 1129–1146.
24.
SeungjinC (2008) Algorithms for orthogonal nonnegative matrix factorization. 2008 IEEE International Joint Conference on Neural Networks (IEEE World Congress on Computational Intelligence), Hong Kong, China, pp. 1828–1832.
25.
ZhangW, ChanKCG, ShibataD, HaynorD (2021) Finding atrophy patterns of grey matter through orthonormal non-negative factorization. Proc SPIE11596, 244–252.
26.
ShuiL, ShibataD, ChanKCG, HaynorDR (2023) Feature extraction by orthonormal projective non-negative matrix factorization and longitudinal association between brain atrophy patterns and Alzheimer’s disease. Alzheimers Dement19, e077295.
27.
PennyWD, FristonKJ, AshburnerJT, KiebelSJ, NicholsTE (2006), Statistical parametric mapping: The analysis of functional brain images. Elsevier.
28.
AsterisM, PapailiopoulosD, DimakisAG (2015) Orthogonal NMF through subspace exploration. Adv Neural Inf Process Syst28 (NIPS 2015).
29.
BabaK, ShibataR, SibuyaM (2004) Partial correlation and conditional correlation as measures of conditional independence. Aust N Z J Stat46, 657–664.
30.
DobraA, LenkoskiA (2011) Copula Gaussian graphical models and their application to modeling functional disability data. Ann Appl Stat5, 969–993.
31.
BenjaminiY, HochbergY (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol57, 289–300.
32.
LenthR, SingmannH, LoveJ, BuerknerP, HerveM (2019) emmeans: Estimated marginal means, aka Least-Squares Means. R package version 1.10.0.
33.
YangZ, OjaE (2010) Linear and nonlinear projective nonnegative matrix factorization. IEEE Trans Neural Netw21, 734–749.
34.
WeilerM, AgostaF, CanuE, CopettiM, MagnaniG, MarconeA, PaganiE, BalthazarML, ComiG, FaliniA, FilippiM (2015) Following the spreading of brain structural changes in Alzheimer’s disease: A longitudinal, multimodal MRI study. J Alzheimers Dis47, 995–1007.
McDonaldCR, McEvoyLK, GharapetianL, Fennema-NotestineC, HaglerDJJr., HollandD, KoyamaA, BrewerJB, DaleAM, Alzheimer’s Disease Neuroimaging Initiative (2009) Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology73, 457–465.
37.
MaX, LiZ, JingB, LiuH, LiD, LiH, Alzheimer’s Disease Neuroimaging Initiative (2016) Identify the atrophy of Alzheimer’s disease, mild cognitive impairment and normal aging using morphometric MRI analysis. Front Aging Neurosci8, 243.
38.
AndersonVM, SchottJM, BartlettJW, LeungKK, MillerDH, FoxNC (2012) Gray matter atrophy rate as a marker of disease progression in AD. Neurobiol Aging33, 1194–1202.
39.
McDonaldCR, GharapetianL, McEvoyLK, Fennema-NotestineC, HaglerDJJr, HollandD, DaleAM, Alzheimer’s Disease Neuroimaging Initiative (2012) Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol Aging33, 242–253.
40.
SarazinM, ChauviréV, GerardinE, ColliotO, KinkingnéhunS, de SouzaLC, Hugonot-DienerL, GarneroL, LehéricyS, ChupinM (2010) The amnestic syndrome of hippocampal type in Alzheimer’s disease: An MRI study. J Alzheimers Dis22, 285–294.
41.
FrisoniGB, JackCR (2011) Harmonization of magnetic resonance-based manual hippocampal segmentation: A mandatory step for wide clinical use. Alzheimers Dement7, pp. 171–174.
Llibre-GuerraJJ, LiY, SchindlerSE, GordonBA, FaganAM, MorrisJC, BenzingerTL, HassenstabJ, WangG, AllegriR (2019) Association of longitudinal changes in cerebrospinal fluid total tau and phosphorylated tau 181 and brain atrophy with disease progression in patients with Alzheimer disease. JAMA Netw Open2, e1917126e1917126.
44.
HammondTC, XingX, WangC, MaD, NhoK, CranePK, ElahiF, ZieglerDA, LiangG, ChengQ (2020) β-amyloid and tau drive early Alzheimer’s disease decline while glucose hypometabolism drives late decline. Commun Biol3, 352.
45.
ChételatG, La JoieR, VillainN, PerrotinA, de La SayetteV, EustacheF, VandenbergheR (2013) Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. Neuroimage Clin2, 356–365.
46.
HilalS, WoltersFJ, VerbeekMM, VandersticheleH, IkramMK, StoopsE, IkramMA, VernooijMW (2018) Plasma amyloid-β levels, cerebral atrophy and risk of dementia: A population-based study. Alzheimers Res Ther10, 1–8.
47.
SturchioA, DwivediAK, YoungCB, MalmT, MarsiliL, SharmaJS, MahajanA, HillEJ, AndaloussiSE, PostonKL (2021) High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis. EClinicalMedicine38, 100988.
48.
ChourakiV, BeiserA, YounkinL, PreisSR, WeinsteinG, HanssonO, SkoogI, LambertJ-C, AuR, LaunerL (2015) Plasma amyloid-β and risk of Alzheimer’s disease in the Framingham Heart Study. Alzheimers Dement11, 249–257.e241.
49.
ShahNS, VidalJ-S, MasakiK, PetrovitchH, RossGW, TilleyC, DeMattosRB, TracyRP, WhiteLR, LaunerLJ (2012) Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: The Honolulu Asia Aging Study. Hypertension59, 780–786.
50.
RitchieSJ, CoxSR, ShenX, LombardoMV, ReusLM, AllozaC, HarrisMA, AldersonHL, HunterS, NeilsonE (2018) Sex differences in the adult human brain: Evidence from 5216 UK biobank participants. Cereb Cortex28, 2959–2975.
51.
GeY, GrossmanRI, BabbJS, RabinML, MannonLJ, KolsonDL (2002) Age-related total gray matter and white matter changes in normal adult brain. Part I: Volumetric MR imaging analysis. Am J Neuroradiol23, 1327–1333.
52.
LotzeM, DominM, GerlachFH, GaserC, LuedersE, SchmidtCO, NeumannN (2019) Novel findings from 2,838 adult brains on sex differences in gray matter brain volume. Sci Rep9, 1671.
53.
FerreiraD, VerhagenC, Hernandez-CabreraJA, CavallinL, GuoCJ, EkmanU, MuehlboeckJS, SimmonsA, BarrosoJ, WahlundLO, WestmanE (2017) Distinct subtypes of Alzheimer’s disease based on patterns of brain atrophy: Longitudinal trajectories and clinical applications. Sci Rep7, 46263.
54.
LinKA, ChoudhuryKR, RathakrishnanBG, MarksDM, PetrellaJR, DoraiswamyPM, Alzheimer’s Disease Neuroimaging Initiative (2015) Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement (N Y)1, 103–110.
55.
RisacherSL, ShenL, WestJD, KimS, McDonaldBC, BeckettLA, HarveyDJ, JackCRJr, WeinerMW, SaykinAJ (2010) Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort. Neurobiol Aging31, 1401–1418.
